Cabio Biotech (Wuhan) Co (688089) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jul 12, 2026
From 26 valuation models · updated 29 days ago
Fair value updated Jul 12, 2026, revised from ¥19.69 to ¥17.46 (−11.3%) since Jun 24, 2026. Share price −26.5% over the past month.
A solid business, screening 122% undervalued on our models.
What matters now
- The price is below even our cautious bear case (¥12.72). The market is more pessimistic than our downside scenario.
- Solid quality (69/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.
How to read this chart
60‑month range ¥6.98 – ¥48.06 · fair‑value band ¥12.72 – ¥21.63 · the ¥7.87 price screens below the ¥17.46 fair value. Dashed = 300-day average. As of Jul 12, 2026.
Analysis
Cabio Biotech (Wuhan) Co (688089) currently trades at ¥7.87, while our model-based Fair Value estimate is ¥17.46, implying the stock looks roughly 121.9% undervalued today. The Quality Score stands at 69/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Cabio Biotech (Wuhan) Co generated revenue of 418M CNY at a net margin of 13.2%. It earns a return on equity of 3.1%. The balance sheet holds a net cash position of 134M CNY. The stock trades on a trailing P/E of 36.8. Fundamentals as of Jul 12, 2026
Our scenario range runs from ¥12.72 (bear case) to ¥21.63 (bull case); at ¥7.87, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 75% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 122%, 688089 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings (¥16.95) versus Dividend Discount (¥3.22). Highest evidence: Growth DCF (80).
Notify me when 688089 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 12, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 71 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products.
Full company description
Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. It offers human and animal nutrition, personal care, and synthetic biology products. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Cabio Biotech (Wuhan) Co reported revenue of ¥575M in FY2025 versus ¥351M in FY2021, a compound +13.1%/yr. Reported net income was ¥157M in FY2025, compounding +5.1%/yr from FY2021.
of which total revenue +12.2 pp · buybacks/dilution −6.4 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 688089: get an alert when its fair value changes →
Peer Group
Biotechnology · 601 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $486.03 | $278.78 | -43% |
| Regeneron Pharmaceuticals, Inc REGN | $664.45 | $594.40 | -11% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
| Celltrion, Inc 068270 | 175,800 KRW | 76,325 KRW | -57% |
| WuXi Biologics (Cayman) Inc 2269 | HK$39.54 | HK$30.42 | -23% |
| Innovent Biologics, Inc 1801 | HK$86.70 | HK$19.66 | -77% |
| Sino Biopharmaceutical Limited 1177 | HK$5.26 | HK$3.36 | -36% |
| ALTEOGEN Inc 196170 | 276,500 KRW | 44,444 KRW | -84% |
| RemeGen Co 688331 | ¥134.02 | ¥26.99 | -80% |
| Biocon Limited BIOCON | ₹440.70 | ₹57.36 | -87% |
Compare Cabio Biotech (Wuhan) Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Cabio Biotech (Wuhan) Co (688089) overvalued or undervalued?
What is the fair value of 688089?
What is the quality score of 688089?
What is the revenue of Cabio Biotech (Wuhan) Co (688089)?
What is the net profit margin of 688089?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Cabio Biotech (Wuhan) Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.